Evidence map›Paper›PMID 27110259›Full record

ArticleHepatitis monthly2016

The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C.

Bita Behnava, Heidar Sharafi, Maryam Keshvari, Ali Pouryasin, Leila Mehrnoush, Shima Salimi, Pegah Karimi Elizee, Mehran Ghazimoghaddam, Seyed Moayed Alavian

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatitis monthly, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03296930 (Effect Of Interferon-Free Direct Acting Antiviral Agents For Treatment Of Hepatitis C Virus Patients On The Normal Kidney), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03296930 phase4unknown statusnot on this mapstarted 2017, after this paper: background citation

Effect Of Interferon-Free Direct Acting Antiviral Agents For Treatment Of Hepatitis C Virus Patients On The Normal Kidney

TypeinterventionalSponsorAssiut UniversityRan2017 to 2018Enrolled100ConditionsAntiviral Drug Adverse ReactionArmsSofosbuvir 400 MG Oral Tablet,, Ombitasvir/paritaprevir/ritonavir
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Hepatitis C Treatment in Patients with Drug Addiction Is Effective or Not Effective?Medical archives (Sarajevo, Bosnia and Herzegovina) · 2018
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Bita BehnavaIran Hepatitis Network, Tehran, IR Iran; Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran; Middle East Liver Diseases (MELD) Center, Tehran, IR Iran.
Heidar SharafiIran Hepatitis Network, Tehran, IR Iran; Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran; Middle East Liver Diseases (MELD) Center, Tehran, IR Iran; Armin Pathobiology Laboratory, Tehran, IR Iran.
Maryam KeshvariIran Hepatitis Network, Tehran, IR Iran; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, IR Iran.
Ali PouryasinIran Hepatitis Network, Tehran, IR Iran; Armin Pathobiology Laboratory, Tehran, IR Iran; Department of Biology, Arsanjan Branch, Islamic Azad University, Arsanjan, IR Iran.
Leila MehrnoushIran Hepatitis Network, Tehran, IR Iran; Middle East Liver Diseases (MELD) Center, Tehran, IR Iran.
Shima SalimiIran Hepatitis Network, Tehran, IR Iran; Middle East Liver Diseases (MELD) Center, Tehran, IR Iran.
Pegah Karimi ElizeeIran Hepatitis Network, Tehran, IR Iran; Middle East Liver Diseases (MELD) Center, Tehran, IR Iran.
Mehran GhazimoghaddamArmin Pathobiology Laboratory, Tehran, IR Iran.
Seyed Moayed AlavianIran Hepatitis Network, Tehran, IR Iran; Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran; Middle East Liver Diseases (MELD) Center, Tehran, IR Iran.
Middle East Liver Disease Center · IRBaqiyatallah University of Medical Sciences · IRHigh Institute for Education and Research in Transfusion Medicine · IRIslamic Azad University of Arsanjan · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatitis C Virus (HCV) is the major cause of liver failure in thalassemic patients. In these patients, iron overload and their comorbidities make difficulties during Pegylated-Interferon (PEG-IFN) and Ribavirin (RBV) therapy.

objectivesWe aimed to assess the impact of polymorphisms near the IL28B gene on virological response in HCV - infected thalassemic patients, who were treated with PEG-IFN and RBV. PATIENTS AND

methodsThis cross - sectional study was conducted on 143 thalassemic patients with chronic hepatitis C, who were treated with a combination of PEG-IFN and RBV regimen. The rs12979860 and rs8099917 polymorphisms were assessed as the most common polymorphisms near the IL28B gene by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.

resultsThe rate of sustained virological response (SVR) was significantly lower in thalassemic patients with HCV genotype-1 infection compared to patients with HCV genotype-3 infection. Among baseline predictors, rs12979860 and rs8099917 polymorphisms were found to be the only parameters associated with achievement of SVR in thalassemic patients with HCV genotype-1 infection however, there was no association between these polymorphisms and the rate of SVR in thalassemic patients with HCV genotype-3 infection.

conclusionsIn HCV genotype-1- infected thalassemic patients with rs12979860 CC genotype and without severe comorbidities, PEG-IFN and RBV combination therapy can be tried yet in those with rs12979860 CT/TT it may be reasonable to treat cases with new direct-acting antivirals.

Indexed as

Genetic PolymorphismHepatitis CPegylated-InterferonRibavirinThalassemia

Identifiers

PMID27110259
PMCPMC4834189
OpenAlexW2240375514

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.